Clinical trial

Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

NCT00862134

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention PR104 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record docetaxel Normalized identity: docetaxelView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Granulocyte colony-stimulating factor Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2009-03-01

PhasePHASE2

Conditions

Non-Small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Interventions

PR104DRUG

docetaxelDRUG · verified · RxNorm: docetaxel

Granulocyte colony-stimulating factorDRUG

Sponsors & collaborators

Proacta, Incorporatedlead sponsor

Mapped research locations

ChicagoIllinois, United States1 PhiladelphiaPennsylvania, United States1 DallasTexas, United States1 BaltimoreMaryland, United States1 MiamiFlorida, United States1 CincinnatiOhio, United States1 San DiegoCalifornia, United States1 MontrealQuebec, Canada1 DurhamNorth Carolina, United States1 Winston-SalemNorth Carolina, United States1 MemphisTennessee, United States1 WichitaKansas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00862134 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.